Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
- ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
- Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Tweets from GSK
-
GSK @GSK
#DYK: The number of people diagnosed with multiple #myeloma from 1990 to 2016 increased by 126% globally. That’s why we are committed to blood #cancer research with the goal of delivering potentially transformational medicines to patients. #ASH19 #mmsm
about 21 hours ago -
GSK @GSK
We are training immune cells to target and potentially destroy tumours. We look forward to showcasing our ongoing efforts at #ASH19.
about 23 hours ago -
GSK @GSK
Congratulations to our CEO Emma Walmsley for her inclusion in @BW's 2019 #Bloomberg50 list of people who are changing the global business landscape. 👏twitter.com/BW/status/1202…n
about 1 day ago
